Share

EORTC supports World Cancer Day 2015

world-cancer-day-2015Cancer knows no boundaries. It has, or will, affect us all, directly or indirectly, during our lifetime. In the face of this disease and its consequences, World Cancer Day was organized to raise awareness of the disease and press governments and individuals across the world to take action.

Tremendous progress has been made in the last 50 years with significant increases in survival. New breakthroughs in molecular biology are allowing us to progress further and target treatments according to the characteristics of tumors. The EORTC, too, has launched a major research program, SPECTA (Screening Patients for Efficient Clinical Trial Access), with the aim of further developing personalized medicines.

Wednesday, 04 February 2015 marks World Cancer Day 2015, and on this day the EORTC, with its long history of improving treatments for patients with cancer, joins the Union for International Cancer Control (UICC), its members, partners, supporters and the entire world in the fight against the global cancer epidemic and promoting cancer awareness.

The EORTC is committed to improving treatments for patients with cancer and improving the quality of life for cancer patients and also, importantly, cancer survivors. In this spirit, the EORTC has organized:

These EORTC events are essential in forging the required partnerships to bring about improvements for all of us, those affected by the impact of cancer. Cancer can have a serious impact on a person’s emotional, physical and mental state and cancer survivors are at risk of diminished quality of life for many years following their diagnosis. The EORTC is committed not just to improving treatments, but also to addressing the myriad problems facing cancer patients and cancer survivors in their daily lives.

John Bean, PhD
EORTC, Medical Science Writer

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023